The CSBI-TEConomy Life Science Workforce Trends Report reflects Continued Resilience Amidst a Global Pandemic, Adjusting to Remote Work, and Advancing a More Diverse and Inclusive Industry. The report debuted at BIO Digital on June 17, 2021.
The additional FDA clearance provides broad flexibility to choose either 1MHz or 2MHz for treatment
PHOENIX, June 8, 2021 /PRNewswire/ — bioSyntagma®, Inc unveiled the world’s first high-plex multi-omic spatial workflow designed for clinical samples and diagnostic applications. Compatible with FFPE and large resections up to an inch in size, the Molecular Fingerprint™ (mPrint) technology has been demonstrated to map tumor microenvironments with custom PCR panels, targeted and total sequencing, and spatial imaging at resolutions ranging from single-cell to complex regions of interest. bioSyntagma’s solution is the first to provide a pathway to diagnostic applications with its proprietary spatial-diagnostic machine learning engine that classifies tissues based on tumor microenvironment. Continue reading
- Phase 0 trial in ARDS subjects estimated completion by end of 1st QTR 2022
- FDA indicates general agreement on required IND-enabling program for ALT-100 mAb in ARDS patients
- ALT-100 humanized mAb manufacturing initiated and speeding toward GMP completion
TUCSON, Ariz., June 14, 2021 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has completed product design lock for the HTG Transcriptome Panel and announced three Early Adopter Program (EAP) collaborators. HTG continues to progress in its development of a planned transcriptome panel using the HTG EdgeSeq technology. This panel, expected to be called the HTG Transcriptome Panel, will measure approximately 20,000 mRNA targets, with a planned research use only commercial launch in the third quarter of 2021.Continue reading
TUCSON, Ariz. – June 14, 2021 – Avery Therapeutics, Inc. (Avery), a privately held, pre-clinical stage therapeutics company announced today that it has completed a Pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA). Avery received FDA feedback on its planned manufacturing and IND-enabling studies for its novel therapeutic candidate, MyCardia™, which is in development for the treatment of ischemic heart failure.Continue reading
The largest study of its kind has unveiled new insights into how genes are regulated in dementia, including discovering 84 new genes linked to the disease.
Phoenix steps into the spotlight on the Innovation Stage. BIO Digital is virtually bringing together more than 5,000 participants from 55 countries for BIO One-on-One Partnering, critical education and networking starting June 10-11 with the new Innovation Stage and Phoenix is there.Continue reading
- U.S. government to purchase at not-for-profit price 200 million doses in 2021 and 300 million in the first half of 2022
- Doses to be donated to approximately 100 low- and lower middle-income countries including those in the African Union via the COVAX Facility
- Effort is part of the companies’ recent pledge of two billion doses to ensure global equitable access to the vaccine
CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to accelerating research and development to address the rising global threat of drug-resistant bacteria, has awarded Accelerate Diagnostics up to $578,000 to develop new fiber optic technology to diagnose sepsis or the risk of sepsis. Accelerate would be eligible for up to $2.1 million in additional funds from CARB-X if the project meets certain milestones.Continue reading